

Ethiopia

Support for Vaccine: HPV

This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Ethiopia																		
2. Vaccine grant number:	17-ETH-08f-Y, 18-ETH-08f-Y, 1820-ETH-19b-X																		
3. Date of Decision Letter:	30/09/2019																		
4. Date of the Partnership Framework Agreement:	23/07/2013																		
5. Programme title:	New Vaccine Support (NVS), HPV, Routine																		
6. Vaccine type:	HPV																		
7. Requested product presentation and formulation of vaccine:	HPV Quadrivalent, 1 dose(s) per vial, LIQUID																		
8. Programme Duration: ¹	2018-2020																		
9. Programme Budget (indicative): ²	(subject to the terms of the Partnership Framework Agreement, if applicable)																		
	<table border="1"> <thead> <tr> <th></th> <th>2018-2019</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> <th>Total²</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>23,882,000</td> <td>11,223,000</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>35,105,000</td> </tr> </tbody> </table>		2018-2019	2020	2021	2022	2023	2024	Total ²	Programme Budget (US\$)	23,882,000	11,223,000	-	-	-	-	35,105,000		
	2018-2019	2020	2021	2022	2023	2024	Total ²												
Programme Budget (US\$)	23,882,000	11,223,000	-	-	-	-	35,105,000												
10. Vaccine introduction grant	<table border="1"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2017</td> <td>17-ETH-08f-Y</td> <td>-</td> </tr> <tr> <td>2018</td> <td>18-ETH-08f-Y</td> <td>2,968,334</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>20 April, 2018</td> <td>2,968,334</td> </tr> </tbody> </table>	Approval			Year	Grant Number	Amount (US\$)	2017	17-ETH-08f-Y	-	2018	18-ETH-08f-Y	2,968,334	Disbursement		Disbursement date	Amount (US\$)	20 April, 2018	2,968,334
Approval																			
Year	Grant Number	Amount (US\$)																	
2017	17-ETH-08f-Y	-																	
2018	18-ETH-08f-Y	2,968,334																	
Disbursement																			
Disbursement date	Amount (US\$)																		
20 April, 2018	2,968,334																		
11. Product switch grant	Not applicable																		
12. Indicative Annual Amounts: ³	(subject to the terms of the Partnership Framework Agreement, if applicable)																		

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	2018-2019	2020	2021
Number of vaccine doses		2,465,300	-
Annual Amounts (US\$)	23,882,000	11,223,000	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	113,300	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	509,767	-	-	-	-
Total co-financing payments (US\$) (including freight)	516,000	-	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	31 March 2020 15 May 2020

<ul style="list-style-type: none"> Countries shall report the actual switch date in the first renewal request following the actual implementation. 	
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>
<p>18. Financial clarifications: Country shall provide the following clarifications to Gavi*:</p> <p>Not applicable</p> <p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>	
<p>19. Other conditions:</p>	

Signed by,

On behalf of Gavi



Thabani Maphosa
 Managing Director, Country Programmes
 30/09/2019